Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6896283 | 0.81 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2HPGDKDM4EGAA | |
| SCHEMBL4062163 | 0.79 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2HPGDDYRK1BDYRK1A | |
| SCHEMBL14511042 | 0.76 | XDH (0.56) | ALDH1A1SMN1; SMN2HPGDXDH | |
| SCHEMBL4063853 | 0.76 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDDYRK1BDYRK1A | |
| SCHEMBL11784276 | 0.75 | CNR1 (0.42) | ALDH1A1SMN1; SMN2DYRK1BDYRK1AAURKA | |
| SCHEMBL7497665 | 0.74 | ADORA1 (0.42) | ALDH1A1SMN1; SMN2HPGDDYRK1BDYRK1A | |
| SCHEMBL8196991 | 0.74 | ADORA1 (0.42) | ALDH1A1SMN1; SMN2HPGDDYRK1BDYRK1A | |
| SCHEMBL6650779 | 0.73 | TYMS (0.62) | ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL24659326 | 0.73 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2HPGDDYRK1BDYRK1A | |
| SCHEMBL9838320 | 0.72 | KDM4E (0.58) | ALDH1A1SMN1; SMN2HPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851217-B1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | 4 AZA BIOSCIENCE NV (BE) | 2008-12-18 | — | — | US | disclosed |
| EP-1851217-A1 | SUBSTITUTED PYRIDO(2,3-D)PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006087229-A1 | SUBSTITUTED PYRIDO (2 , 3-D) PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | PNPO, TPMT, TNF | ALDH1A1 1197/4885SMN1; SMN2 688/4885HPGD 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.